Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes

Autor: Parameswaran Hari, Jeanette Carreras, Koen van Besien, Brent R. Logan, Philip J. Bierman, Richard E. Champlin, Hillard M. Lazarus, Joseph W. Fay, Roberta King, Gene Nelson, Julie M. Vose, Arturo Molina
Rok vydání: 2009
Předmět:
Male
Oncology
Transplantation Conditioning
Lymphoma
medicine.medical_treatment
Follicular lymphoma
Graft vs Host Disease
Hematopoietic stem cell transplantation
0302 clinical medicine
Risk Factors
hemic and lymphatic diseases
Cumulative incidence
Child
Myeloablative
Lymphoma
Non-Hodgkin

Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
Tissue Donors
3. Good health
Treatment Outcome
Child
Preschool

030220 oncology & carcinogenesis
Female
Adult
Unrelated donor
medicine.medical_specialty
Adolescent
Article
Young Adult
03 medical and health sciences
Age Distribution
Internal medicine
medicine
Humans
Transplantation
Homologous

Survival analysis
Aged
Retrospective Studies
Transplantation
business.industry
medicine.disease
Survival Analysis
Peripheral T-cell lymphoma
Surgery
business
Follow-Up Studies
030215 immunology
Zdroj: Biology of Blood and Marrow Transplantation. 15:554-563
ISSN: 1083-8791
Popis: We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.
Databáze: OpenAIRE